ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 27, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 27, 2012
News
Amgen Settles False Claims Act Allegations
By Amy Ritter
Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.
FDA Issues Final Guidance on Limiting the Use of Certain Phthalates as Excipients
By Patricia Van Arnum
The agency recommends to avoid the use of to dibutyl phthalate and di(2-ethylhexyl) phthalate in CDER-regulated drug and biologic products, including prescription and nonprescription products.
FDA Approves First Anthrax Antitoxin
By Amy Ritter
Anthrax antitoxin is the first monoclonal antibody approved under FDA's Animal Efficacy Rule, and the first product from BARDA's Project Bioshield to receive FDA approval.
First Commercially-Available Mycoplasma Detection Test Accepted by FDA
By Adeline Siew, PhD
Roche's MycoTOOL, which offers rapid detection of mycoplasms based on a polymerase chain reaction (PCR) test, has received FDA acceptance.
University of Connecticut Studies Drug-Carrying Nanoparticles
By Jennifer Markarian
A University of Connecticut chemical engineering professor received a National Science Foundation grant to study how nanoparticles flow in the bloodstream, which is crucial for their use in drug delivery.
Week of December 24, 2012: AAIPharma Expands Parenteral Drug Capacity; Novartis Buys Dendreon Plant; and More
AAIPharma Expands Parenteral Drug Capacity; Novartis Buys Dendreon Plant; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here